- Loxoprofen Impurity D
-
- $0.00 / 10mg
-
2024-12-23
- CAS:1091621-61-2
- Min. Order: 10mg
- Purity: 95%+
- Supply Ability: 100000
|
| | Loxoprofen Ring-opening IMpurity Basic information |
| Product Name: | Loxoprofen Ring-opening IMpurity | | Synonyms: | Loxoprofen Ring-opening IMpurity;Loxoprofen Impurity K;Benzenehexanoic acid, 4-(1-carboxyethyl)-δ-oxo-;Loxoprofen sodium degrades impurity B;4-(1-Carboxyethyl)-d-oxo-benzenehexanoic Acid;4-(1-Carboxyethyl)-δ-oxo-benzenehexanoic Acid;4-(1-Carboxyethyl)-δ-oxo-benzenehexanoic Acid;Bendamustine Impurity: 6-[4-(1-Carboxy-ethyl)-phenyl]-5-oxo-hexanoic acid | | CAS: | 1091621-61-2 | | MF: | C15H18O5 | | MW: | 278.3 | | EINECS: | | | Product Categories: | | | Mol File: | 1091621-61-2.mol |  |
| | Loxoprofen Ring-opening IMpurity Chemical Properties |
| Boiling point | 504.8±35.0 °C(Predicted) | | density | 1.238±0.06 g/cm3(Predicted) | | pka | 4.32±0.10(Predicted) |
| | Loxoprofen Ring-opening IMpurity Usage And Synthesis |
| Uses | 4-(1-Carboxyethyl)-δ-oxo-benzenehexanoic Acid is a degradation product of Loxoprofen (L472900, Na salt), a non-selective nonsteroidal anti-inflammatory drug (NSAID) that has been effective in reducing atherosclerosis in mice by reducing inflammation. It becomes active after metabolism in the body and inhibits the activation of cyclooxygenase. |
| | Loxoprofen Ring-opening IMpurity Preparation Products And Raw materials |
|